Magle Chemoswed Q4: Initial take - Redeye

Redeye leaves an initial comment following the Q4 report published by Magle this morning. The company reported a higher sales figure than expected, a 25% y/y growth, bolstered by increased revenue from its DSM products. While OPEX and COGS were slightly above our expectations, this still resulted in a higher EBIT than expected. Overall, we are encouraged by the company’s Q4 report.

Länk till analysen i sin helhet: https://www.redeye.se/research/981162/magle-chemoswed-q4-initial-take?utm_source=finwire&utm_medium=RSS